Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a price target of $77, implying a potential surge of about 174%. This announcement follows the publication of “stellar results” from the Phase 2a trial for RAP-219 in refractory focal epilepsy.
Keeping in view the year-to-date returns posted by Rapport Therapeutics, Inc., the company outperformed the market by an impressive 45%. What’s even more interesting about the company is its recent data, which is defined by a large market of 1.8 million patients in the U.S., with 40% of them continuing to be treatment resistant.
During the presentation at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, the leadership expressed enthusiasm about its RAP-219, which they view as a multibillion-dollar market opportunity. As stated by the CEO, Abraham Ceesay,
And that’s really defined by a novel MOA with RAP-219; two, efficacy that we think is really best-in-class from what we’ve seen from our proof-of-concept study, a drug that’s generally well tolerated and consistent with precision biology.
Rapport Therapeutics, Inc., headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company that develops medicines for individuals living with central nervous system disorders. Incorporated in 2022, the company is committed to developing therapies with enhanced efficacy.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
